investor losses

CVRx faces securities fraud investigation after stock collapsed 46.3%-73% across 2025-2026 following weak Q1 revenue and repeated guidance cuts.

Three companies face shareholder class actions alleging material misstatements on clinical trials, operations, and expenses. Lead plaintiff deadlines set for April 2026.

Kaskela Law investigates Priority Technology Holdings ($PRTH) for alleged securities violations as stock falls 33% from $7.50 to $5.00 since October 2025.

ODDITY Tech ($ODD) faces class action lawsuit over undisclosed algorithm changes from major ad partner that inflated customer acquisition costs, triggering 49% stock plunge.

uniQure stock plunged 49% after FDA disagreement on gene therapy trial design. Investors with losses eligible to join class action lawsuit by April 2026.

Eos Energy ($EOSE) faces securities fraud lawsuit after 2025 revenue of $114.2M fell far short of $150-160M guidance due to production delays.

Rosen Law Firm investigates $ELWT over financial restatement involving revenue recognition errors. Stock fell 6.8% following disclosure of adjustments to first nine months of 2025.

NuScale Power faces securities class action alleging misrepresentations about strategic partner ENTRA1 Energy's nuclear experience. April 20, 2026 deadline applies.

Hub Group restates Q1-Q3 2025 financials after accounting error. Stock drops 18.3% on disclosure; law firm investigates shareholder claims.

Kahn Swick & Foti sues Navan for allegedly concealing 39% spike in sales/marketing expenses to $95M in Q3 2025 during October IPO. Deadline April 24, 2026.

ImmunityBio hit with securities fraud class action following FDA warning letter over misleading Anktiva cancer therapy ads. Stock fell 21% to $7.42.

Three companies face securities class action suits alleging material misstatements. Investors must apply by May 18, 2026 for $GEMINI; earlier deadlines for $SLNO and $NAVAN.

Law firm files class action against $ENPH for allegedly overstating inventory management and financial prospects during 2025.

$CHOW crashed 84.3% after alleged market manipulation scheme using fake financial advisors. Class action lawsuit filed for September-December 2025 investors.

Class action lawsuit filed against $MEDP over missed Q4 2025 book-to-bill guidance. Stock fell 16% on February 9, 2026. Lead plaintiff deadline set for June 8, 2026.

Pomerantz Law Firm filed class action against $AMC over alleged securities fraud regarding APE preferred equity units excluded from special dividend. Investors must act by April 20, 2026.

Pomerantz Law Firm filed class action against $QURE after 49% stock decline following FDA concerns over gene therapy study data adequacy.

PomDoctor stock plummeted 91% to $0.50 from $6.09 amid pump-and-dump fraud allegations. Pomerantz Law Firm filed class action; investors have until April 6, 2026 to claim losses.

Kyndryl Holdings faces 55% stock collapse after SEC financial reporting investigation and executive departures. Class action lawsuit filed; deadline April 13, 2026.

Law firm Faruqi & Faruqi investigates Medpace for alleged securities fraud over misleading backlog statements. Stock plunged 15.9% after disappointing guidance, with June 8, 2026 deadline for lead plaintiff claims.